T315I mutation
Term · Oncology and biomedicine · MLC-T-ONC-008476
A type of mutation (change) in the BCR::ABL1 fusion protein, which is an abnormal protein found in most people with chronic myelogenous leukemia and in some with acute lymphoblastic leukemia. The T315I mutation may make cancer cells resistant (unable to respond) to anticancer drugs called tyrosine kinase inhibitors. Checking for the T315I mutation in cancer cells may help plan cancer treatment.
| Identifier | MLC-T-ONC-008476 |
|---|---|
| Field | Oncology and biomedicine |
| References | NCI Dictionary of Cancer Terms |
Record as JSON
{
"id": "MLC-T-ONC-008476",
"term": "T315I mutation",
"field": "Oncology and biomedicine",
"definition": "A type of mutation (change) in the BCR::ABL1 fusion protein, which is an abnormal protein found in most people with chronic myelogenous leukemia and in some with acute lymphoblastic leukemia. The T315I mutation may make cancer cells resistant (unable to respond) to anticancer drugs called tyrosine kinase inhibitors. Checking for the T315I mutation in cancer cells may help plan cancer treatment.",
"references": [
"NCI Dictionary of Cancer Terms"
],
"url": "https://mlchart.com/terminology/oncology/t315i-mutation/"
}
Record 15,917 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.